Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy
P Tebas, WG Powderly, S Claxton, D Marin… - Aids, 2000 - journals.lww.com
P Tebas, WG Powderly, S Claxton, D Marin, W Tantisiriwat, SL Teitelbaum, KE Yarasheski
Aids, 2000•journals.lww.comBackground The use of highly active antiretroviral therapy (HAART) has been associated
with multiple metabolic complications whose pathogenesis is poorly understood at the
present time. Methods We performed a cross-sectional analysis of whole-body, lumbar spine
(L 1–L 4) and proximal femur bone mineral density in 112 male subjects (HIV-infected
patients on HAART that included a protease inhibitor, HIV-infected patients not receiving a
protease inhibitor and healthy seronegative adults) using dual energy x-ray absorptiometry …
with multiple metabolic complications whose pathogenesis is poorly understood at the
present time. Methods We performed a cross-sectional analysis of whole-body, lumbar spine
(L 1–L 4) and proximal femur bone mineral density in 112 male subjects (HIV-infected
patients on HAART that included a protease inhibitor, HIV-infected patients not receiving a
protease inhibitor and healthy seronegative adults) using dual energy x-ray absorptiometry …
Abstract
Background
The use of highly active antiretroviral therapy (HAART) has been associated with multiple metabolic complications whose pathogenesis is poorly understood at the present time.
Methods
We performed a cross-sectional analysis of whole-body, lumbar spine (L 1–L 4) and proximal femur bone mineral density in 112 male subjects (HIV-infected patients on HAART that included a protease inhibitor, HIV-infected patients not receiving a protease inhibitor and healthy seronegative adults) using dual energy x-ray absorptiometry.
Results
Men receiving protease inhibitors had a higher incidence of osteopenia and osteoporosis according to World Health Organization definitions: relative risk= 2.19 (95% confidence interval 1.13–4.23)(P= 0.02). Subjects receiving protease inhibitors had greater central: appendicular adipose tissue ratios than the other two groups (P< 0.0001). There was no relationship between the central: appendicular fat ratio and the lumbar spine or proximal femur bone mineral density t-or z-scores, suggesting that osteoporosis and body fat redistribution are independent side effects of HAART.
Conclusions
Osteopenia and osteoporosis are unique metabolic complications associated with protease inhibitor-containing potent antiretroviral regimens, that appear to be independent of adipose tissue maldistribution.
Lippincott Williams & Wilkins